Epstein-barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12251-12261

  Bentz, Gretchen L ^b   Shackelford, Julia ^b   Paganoa, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON REGULATORY FACTOR 7; LATENT MEMBRANE PROTEIN 1; LYSINE; MESSENGER RNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EMBRYO; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOBLASTOID CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; SUMOYLATION; TRANSCRIPTION INITIATION; VIRUS LATENCY;

CELL NUCLEUS; CHROMATIN; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-7; LUCIFERASES; LYSINE; MUTAGENESIS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SUMOYLATION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84869120419     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01407-12     Document Type: Article

References (46)

1. Bailey D, O'Hare P. 2004. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J. Biol. Chem. 279:692-703.
2. Bentz GL, Whitehurst CB, Pagano JS. 2011. Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. J. Virol. 85:10144-10153.
3. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M. 2001. Mechanism of action of a novel latent membrane protein-1 dominant negative. J. Biol. Chem. 276:1195-1203.
4. Calender A, et al. 1987. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 84:8060-8064.
5. Calender A, Cordier M, Billaud M, Lenoir GM. 1990. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int. J. Cancer 46:658-663.
6. Chang TH, et al. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5:e1000493. doi:10.1371/journal.ppat.1000493.
7. Cherney BW, Sgadari C, Kanegane C, Wang F, Tosato G. 1998. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 91:2491-2500.
8. Farlik M, et al. 2012. Contribution of a TANK-binding kinase 1-interferon (IFN) regulatory factor 7 pathway to IFN-gamma-induced gene expression. Mol. Cell. Biol. 32:1032-1043.
9. Gires O, et al. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:3064-3073.
10. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. 2006. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281:16117-16127.
11. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360.
12. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
13. Honda K, et al. 2005. IRF-7 is the master regulator of type-I interferondependent immune responses. Nature 434:772-777.
14. Huye LE, Ning S, Kelliher M, Pagano JS. 2007. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27:2910-2918.
15. Izumi M, Yatagai F, Hanaoka F. 2001. Cell cycle-dependent proteolysis and phosphorylation of human Mcm10. J. Biol. Chem. 276:48526-48531.
16. Kerscher O. 2007. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 8:550-555.
17. Kerscher O, Felberbaum R, Hochstrasser M. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22:159-180.
18. Kim EJ, Park JS, Um SJ. 2008. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1. Biochem. Biophys. Res. Commun. 377:952-956.
19. Kroetz MB. 2005. SUMO: a ubiquitin-like protein modifier. Yale J. Biol. Med. 78:197-201.
20. Kubota T, et al. 2008. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 283:25660-25670.
21. Lefort S, Soucy-Faulkner A, Grandvaux N, Flamand L. 2007. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J. Virol. 81:10950-10960.
22. Li HP, Chang YS. 2003. Epstein-Barr virus latent membrane protein 1: structure and functions. J. Biomed.Sci. 10:490-504.
23. Liang Q, et al. 2011. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187:4754-4763.
24. Lin R, Mamane Y, Hiscott J. 2000. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:34320-34327.
25. Miller WE, Mosialos G, Kieff E, Raab-Traub N. 1997. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J. Virol. 71:586-594.
26. Nakagawa K, Yokosawa H. 2002. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett. 530:204-208.
27. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS. 2008. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28:6536-6546.
28. Ning S, Hahn AM, Huye LE, Pagano JS. 2003. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J. Virol. 77:9359-9368.
29. Ning S, Huye LE, Pagano JS. 2005. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J. Virol. 79:11671-11676.
30. Ning S, Pagano JS. 2010. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. J. Virol. 84:6130-6138.
31. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 12:399-414.
32. Pagano JS. 2009. EBV diseases, p 217-240. In Damania B, Pipas JM (ed), DNA tumor viruses. Springer Science + Business Media, New York, NY.
33. Pagano JS, et al. 2004. Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14:453-471.
34. Paun A, Pitha PM. 2007. The IRF family, revisited. Biochimie 89:744-753.
35. Reverter D, Lima CD. 2004. A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. Structure 12:1519-1531.
36. Sakaguchi S, et al. 2003. Essential role of IRF-3 in lipopolysaccharideinduced interferon-beta gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306:860-866.
37. Shen LN, Dong C, Liu H, Naismith JH, Hay RT. 2006. The structure of SENP1-SUMO-2 complex suggests a structural basis for discrimination between SUMO paralogues during processing. Biochem. J. 397:279-288.
38. Song J, Zhang Z, Hu W, Chen Y. 2005. Small ubiquitin-like modifier(SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J. Biol. Chem. 280:40122-40129.
39. Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E. 2008. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl. Acad. Sci. U. S. A. 105:18448-18453.
40. Xu Z, Au SW. 2005. Mapping residues of SUMO precursors essential in differential maturation by SUMO-specific protease, SENP1. Biochem. J. 386:325-330.
41. Yu Y, Wang SE, Hayward GS. 2005. The KSHV immediate-early tran scription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22:59-70.
42. Zhang L, Pagano JS. 2000. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J. Virol. 74:1061-1068.
43. Zhang L, Pagano JS. 2001. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J. Virol. 75:341-350.
44. Zhang L, Pagano JS. 2001. Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation. Semin. Cancer Biol. 11:445-453.
45. Zhang L, Pagano JS. 1997. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17:5748-5757.
46. Zhang L, Pagano JS. 2002. Structure and function of IRF-7. J. Interferon Cytokine Res. 22:95-101.